Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years

European Journal of Cancer

Volumn 34, Issue 8, 1998, Pages 1204-1207

  Bower, M ^a   Rustin, G J S ^b   Newlands, E S ^a   Holden, L ^a   Short, D ^a   Foskett, M ^a   Bagshawe, K D ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Choriocarcinoma; Menopause

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FOLINIC ACID; HYDROXYUREA; MERCAPTOPURINE; METHOTREXATE; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; EARLY MENOPAUSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TROPHOBLASTIC TUMOR;

6-MERCAPTOPURINE; ADULT; ANTINEOPLASTIC AGENTS; CHORIOCARCINOMA; DACTINOMYCIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYUREA; LEUCOVORIN; MENOPAUSE, PREMATURE; METHOTREXATE; MIDDLE AGED; PREGNANCY; RETROSPECTIVE STUDIES; RISK FACTORS; TROPHOBLASTIC NEOPLASMS;

EID: 0032126293     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00059-8     Document Type: Article

References (23)

1. 1. Horning S, Hoppe R, Caplan H, Rosenberg S. Female reproductive potential after treatment of Hodgkin's disease. N Engl J Med 1981, 304, 1377-1382.
2. 2. Schilsky R, Sherins R, Hubbard S, Wesley M, Young R, Vita V de. Long term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med 1981, 71, 552-556.
3. 3. Rustin GJS, Booth M, Dent J, et al. Pregnancy after cyotoxic chemotherapy gestational trophoblastic tumours. Br Med J 1984, 288, 103-106.
4. 4. Goldstein D, Berkowitz R, Bernstein M. Reproductive performance after molar pregnancy and gestational trophoblastic tumours. Clin Obstet Gynecol 1984, 27, 221-227.
5. 5. Clark ST, Radford JA, Crowther D, Swindell R, Shalet SM. Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen. J Clin Oncol 1995, 13(1), 134-139.
6. 6. Rustin GJ, Newlands ES, Lutz JM, et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 1996, 14(10), 2769-2773.
7. 7. Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer 1976, 38, 1373-1385.
8. 8. Bagshawe KD, Dent J, Newlands ES, et al. The role of low dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol 1989, 96, 795-802.
9. 9. Newlands ES, Bagshawe KD, Begent RHJ, et al. Developments in chemotherapy for medium and high risk patients with gestational trophoblastic tumours (1974-1984). Br J Obstet Gynaecol 1986, 93, 63-69.
10. 10. Newlands ES, Bagshawe KD, Begent RHJ, et al. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regime in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol 1991, 98, 550-557.
11. 11. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
12. 12. Peto R, Pike M, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient: II analysis and examples. Br J Cancer, 1977, 35, 1-39.
13. 13. Hendry WF, Stedronska J, Jones CR, Blackmore CA, Barrett A, Peckham MJ. Semen analysis in testicular cancer and Hodgkin's disease: pre- and post-treatment findings and implications for cryopreservation. Br J Urol 1983, 55(6), 769-773.
14. 14. Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer 1983, 52(6), 988-993.
15. 15. Bulbrook RD, Moore JW, Clark GM, Wang DY, Tong D, Hayward JL. Plasma oestradiol and progesterone levels in women with varying degrees of risk of breast cancer. Eur J Cancer 1978, 14(12), 1369-1375.
16. 16. Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977, 39(4), 1403-1409.
17. 17. Sobrinho LG, Levine RA, DeConti RC. Amenorrhoea in patients with Hodgkin's disease treated with antineoplastic agents. Am J Obstet Gynecol 1971, 109(1), 135-139.
18. 18. Shamberger RC, Sherins RJ, Ziegler JL, Glatstein E, Rosenberg SA. Effects of postoperative adjuvant chemotherapy and radiotherapy on ovarian function in women undergoing treatment for soft tissue sarcoma. J Natl Cancer Inst 1981, 67(6), 1213-1218.
19. 19. Choo YC, Chan SY, Wong LC, Ma HK. Ovarian dysfunction in patients with gestational trophoblastic neoplasia treated with short intensive courses of etoposide (VP-16-213). Cancer 1985, 55(10), 2348-2352.
20. 20. Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic-induced ovarian failure in women with Hodgkin's disease. I. Hormone function. J Am Med Assoc 1979, 242(17), 1877-1881.
21. 21. Fisher B, Sherman B, Rockette H, Redmond C, Margolese R, Fisher ER. 1-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of disease-free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers. Cancer 1979, 44(3), 847-857.
22. 22. Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985, 21(5), 601-605.
23. 23. McKinlay S, Brambilla D, Posner J. The normal menopause transition. Maturitas 1992, 14, 103-115.